Rapid Innovation is Reshaping Oncology: Stocks in Focus

Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.

Zacks Investment Research • Feb 5, 2026

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström's Macroglobulinemia. The outpatient study evaluates ImmunityBio's novel, off-the-shelf CD19-targeted high-affinity natural killer (NK) cell therapy.

Business Wire • Feb 2, 2026

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

Traders targeting heavily shorted stocks are looking to play one of two sides: betting on a company's downfall or hunting for a short squeeze.

Benzinga • Feb 2, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc.  ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext.

PRNewsWire • Jan 29, 2026

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

Expand NASDAQ: IBRX ImmunityBio Today's Change (-3.72%) $-0.24 Current Price $6.21 Key Data Points Market Cap $6.4B Day's Range $6.16 - $6.75 52wk Range $1.83 - $8.28 Volume 37M Avg Vol 23M Gross Margin 80.41% ImmunityBio (IBRX 3.72%), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer, and investors are watching next steps on the planned data resubmission path.

The Motley Fool • Jan 26, 2026

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month

Expand NASDAQ: IBRX ImmunityBio Today's Change (-12.13%) $-0.89 Current Price $6.45 Key Data Points Market Cap $7.2B Day's Range $6.43 - $7.88 52wk Range $1.83 - $8.28 Volume 75M Avg Vol 22M Gross Margin 80.41% ImmunityBio (IBRX 12.13%), an immunity-focused biotech, closed Friday's session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.

The Motley Fool • Jan 23, 2026

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a chemotherapy-free combination immunotherapy regimen in patients with second-line recurrent or progressive glioblastoma (GBM), as well as patients treated under single-patient INDs (spINDs) across first- t.

Business Wire • Jan 23, 2026

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses

Expand NASDAQ: IBRX ImmunityBio Today's Change (6.79%) $0.44 Current Price $6.92 Key Data Points Market Cap $6.4B Day's Range $5.71 - $7.10 52wk Range $1.83 - $7.98 Volume 96M Avg Vol 19M Gross Margin 80.41% ImmunityBio (IBRX +6.79%), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do after the company's share price tripled in just three weeks this year.

The Motley Fool • Jan 21, 2026

ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission

IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.

Zacks Investment Research • Jan 21, 2026

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

ImmunityBio Inc. (NASDAQ: IBRX) on Tuesday said it plans to submit additional information to the U.S. Food and Drug Administration (FDA) within 30 days following a Type B end-of-phase meeting related to its supplemental biologics license application for Anktiva in papillary non-muscle invasive bladder cancer (NMIBC).

Benzinga • Jan 20, 2026